These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37162497)

  • 1. Relugolix in Clinical Practice: The Best Route for All?
    Cordes LM; Karzai F; Figg WD; Madan RA
    Oncologist; 2023 Aug; 28(8):647-650. PubMed ID: 37162497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
    Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
    Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First Oral Hormone for Treating Prostate Cancer.
    Aschenbrenner DS
    Am J Nurs; 2021 Apr; 121(4):22-23. PubMed ID: 33755620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
    Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS; Blank J; Graff JN
    Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.
    Kasparian S; Wei O; Tsai NC; Palmer J; Pal S; Lyou Y; Dorff T
    Oncologist; 2023 Aug; 28(8):699-705. PubMed ID: 36888587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.
    Chow AK; Vourganti S; Konety BR
    Eur Urol; 2021 Sep; 80(3):386. PubMed ID: 34092438
    [No Abstract]   [Full Text] [Related]  

  • 9. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
    Liu YF; Fu SQ; Yan YC; Gong BB; Xie WJ; Yang XR; Sun T; Ma M
    Drug Des Devel Ther; 2021; 15():639-649. PubMed ID: 33623372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relugolix: A Review in Advanced Prostate Cancer.
    Shirley M
    Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relugolix in the management of prostate cancer.
    Sahu KK; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment.
    Lv J; Lin J
    Asian J Androl; 2021; 23(3):229-230. PubMed ID: 33243960
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Mahal BA; D'Amico AV; Nguyen PL
    Eur Urol; 2020 Nov; 78(5):e195. PubMed ID: 32863056
    [No Abstract]   [Full Text] [Related]  

  • 14. Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer.
    Sachdev S; Zhang H; Hussain M
    Eur Urol; 2020 Aug; 78(2):193-194. PubMed ID: 32345524
    [No Abstract]   [Full Text] [Related]  

  • 15. Relugolix: First Global Approval.
    Markham A
    Drugs; 2019 Apr; 79(6):675-679. PubMed ID: 30937733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer.
    Adekunle OA; Seoane-Vazquez E; Brown LM
    J Am Pharm Assoc (2003); 2023; 63(3):817-824.e3. PubMed ID: 36653276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Shore ND; Dearnaley D; Tombal B
    Eur Urol; 2020 Nov; 78(5):e196-e197. PubMed ID: 32838997
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances with androgen deprivation therapy for prostate cancer.
    Yu EM; Aragon-Ching JB
    Expert Opin Pharmacother; 2022 Jun; 23(9):1015-1033. PubMed ID: 35108137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 HERO Trial Finds Relugolix to Be Superior to Leuprolide in Prostate Cancer.
    Slater H
    Oncology (Williston Park); 2020 Jul; 34(7):252. PubMed ID: 32674208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT).
    Skolarus TA; Hawley ST; Wittmann DA; Forman J; Metreger T; Sparks JB; Zhu K; Caram MEV; Hollenbeck BK; Makarov DV; Leppert JT; Shelton JB; Shahinian V; Srinivasaraghavan S; Sales AE
    Implement Sci; 2018 Nov; 13(1):144. PubMed ID: 30486836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.